Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010
Matteo Zignol, Wayne van Gemert, Dennis Falzon, Charalambos Sismanidis, Philippe Glaziou, Katherine Floyd & Mario Raviglione
Volume 90, Number 2, February 2012, 111-119D
Table 2. Countries and territories reporting dataa on extensively drug-resistant tuberculosis (XDR-TB), 2007–2010
| Country or territory | Source | Year | No. of cases of MDR-TB | MDR-TB cases with DST results for 2nd-line drugs | No. of cases of XDR-TB (%) |
|---|---|---|---|---|---|
| Albania | Surveillance | 2010 | 2 | 2 | 0 (0.0) |
| Australia | Surveillance | 2010 | 32 | 32 | 1 (3.1) |
| Austria | Surveillance | 2010 | 15 | 15 | 1 (6.7) |
| Bangladesh (14 districts covering 30 million population)b | Surveillance | 2008 | 168 | 168 | 1 (0.6) |
| Belgium | Surveillance | 2009 | 10 | 10 | 3 (30.0) |
| Botswana | Survey | 2008 | 32 | 24 | 0 (0.0) |
| Bulgaria | Surveillance | 2008 | 32 | 28 | 0 (0.0) |
| Canada | Surveillance | 2010 | 15 | 14 | 1 (7.1) |
| China | Survey | 2008 | 401 | 401 | 29 (7.2) |
| China, Hong Kong Special Administrative Region | Surveillance | 2009 | 3 | 3 | 0 (0.0) |
| China, Macao Special Administrative Region | Surveillance | 2010 | 6 | 6 | 0 (0.0) |
| Cyprus | Surveillance | 2008 | 1 | 1 | 0 (0.0) |
| Czech Republic | Surveillance | 2008 | 11 | 10 | 1 (10.0) |
| Denmark | Surveillance | 2007 | 2 | 2 | 0 (0.0) |
| Estonia | Surveillance | 2010 | 63 | 61 | 12 (19.7) |
| Georgia | Surveillance | 2010 | 359 | 313 | 30 (9.6) |
| Greece | Surveillance | 2009 | 14 | 9 | 3 (33.3) |
| Guam | Surveillance | 2010 | 2 | 2 | 0 (0.0) |
| Iceland | Surveillance | 2008 | 1 | 1 | 0 (0.0) |
| India, Gujarat state | Survey | 2006 | 216 | 216 | 7 (3.2) |
| Israel | Surveillance | 2010 | 12 | 12 | 1 (8.3) |
| Italy | Surveillance | 2009 | 82 | 32 | 1 (3.1) |
| Latvia | Surveillance | 2010 | 87 | 86 | 13 (15.1) |
| Marshall Islands | Surveillance | 2010 | 1 | 1 | 0 (0.0) |
| Montenegro | Surveillance | 2009 | 1 | 1 | 0 (0.0) |
| Namibia | Survey | 2008 | 100 | 100 | 0 (0.0) |
| Norway | Surveillance | 2008 | 4 | 4 | 0 (0.0) |
| Oman | Surveillance | 2010 | 1 | 1 | 0 (0.0) |
| Paraguay | Survey | 2008 | 8 | 8 | 0 (0.0) |
| Poland | Surveillance | 2008 | 52 | 52 | 5 (9.6) |
| Qatar | Surveillance | 2010 | 4 | 4 | 0 (0.0) |
| Singapore | Surveillance | 2010 | 3 | 3 | 0 (0.0) |
| Slovakia | Surveillance | 2010 | 1 | 1 | 0 (0.0) |
| South Africa | Surveillance | 2008 | 8026 | 5451 | 572 (10.5) |
| Swaziland | Survey | 2009 | 122 | 122 | 1 (0.8) |
| Sweden | Surveillance | 2009 | 13 | 9 | 0 (0.0) |
| Switzerland | Surveillance | 2010 | 8 | 8 | 0 (0.0) |
| Tajikistan, Dushanbe city and Rudaki district | Survey | 2009 | 100 | 100 | 21 (21.0) |
| Former Yugoslav Republic of Macedonia | Surveillance | 2010 | 7 | 5 | 1 (20.0) |
| United Kingdom of Great Britain and Northern Ireland | Surveillance | 2009 | 58 | 40 | 2 (5.0) |
| United States of America | Surveillance | 2010 | 92 | 59 | 1 (1.7) |
DST, drug susceptibility testing; MDR-TB, multidrug resistant tuberculosis.
a Data from the most recent year are shown.
b Only previously treated cases.
Note: The data were obtained from the World Health Organization.10,11